A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 22 Jan 2024 Interventional study model changed to sequential, number of treatment arms has been changed to 3
- 22 Jan 2024 Status changed from withdrawn prior to enrolment to discontinued.
- 08 May 2020 Status changed from completed to withdrawn prior to enrolment.